Kisspeptin-10
Kisspeptin-10 scored 5.7 / 10 (⚖️ Neutral) on the BioHarmony scale as a Substance → Peptide → Neuropeptide.
Kisspeptin-10 is an investigational reproductive neuropeptide that activates the HPG axis through the KISS1R receptor. Single subcutaneous kisspeptin-54 triggered egg maturation in 95 percent of women at high OHSS risk, per Abbara 2015, but kisspeptin-10 itself has thin direct human data and a minutes-long half-life.
What is Kisspeptin-10?
Kisspeptin-10 is the master upstream switch for the reproductive axis, and that is the cleanest way to understand why it scores where it does. It is the minimal active fragment of kisspeptin, the natural signal that turns the whole hypothalamic-pituitary-gonadal system on. It activates the KISS1R receptor on GnRH neurons, which fire and drive the pituitary to release LH and FSH, which in turn drive your own testosterone or estradiol and gamete production. People born with a broken version of this receptor never enter puberty, which is the strongest proof you can get that this pathway is genuinely central, per Seminara 2003. It sits one step upstream of hormone replacement like TRT, stimulating your body to make hormones rather than supplying them.
Here is the honest catch, and it shapes the whole report. The strongest human trials, in IVF egg maturation and in sexual desire, mostly used the longer kisspeptin-54, while the kisspeptin-10 form people actually buy has thinner direct human data and a half-life measured in minutes. That short half-life means the trial effects came from intravenous infusions, not the single under-the-skin shots most self-experimenters attempt. It is also investigational, not approved, and sold grey-market. So the score reflects a rare grey-market peptide standing on a genuinely first-rate academic research program, capped by an isoform gap and impractical kinetics.
Terminology
A few terms decide how you read this report, because the gap between an elegant mechanism and a practical, proven protocol is exactly where kisspeptin-10 lives. The distinctions between the two isoforms, the route, and the pulsatile signaling pattern change the interpretation completely, so they are worth defining before the dimension detail. The single most important idea is that kisspeptin sits at the very top of a hormone chain, so a small upstream signal cascades into large downstream changes in your sex hormones. The second is that the form name matters: kisspeptin-54 and kisspeptin-10 are not the same molecule, and most of the strong human data belong to the longer one. The third is that timing beats dose, because the reproductive axis is wired to read pulses rather than a constant level, and getting that wrong can flip the whole effect into suppression.
- HPG axis: The hypothalamic-pituitary-gonadal axis. The hormone chain that runs from the brain to the gonads and controls reproduction and sex hormones.
- GnRH: Gonadotropin-releasing hormone. The hypothalamic signal, downstream of kisspeptin, that tells the pituitary to release LH and FSH.
- LH and FSH: Luteinizing hormone and follicle-stimulating hormone. The pituitary hormones that drive the gonads to make testosterone, estradiol, eggs, and sperm.
- KISS1R: The kisspeptin receptor, also called GPR54. The target kisspeptin-10 binds to switch the axis on.
- Kisspeptin-54 (KP-54): The longer parent peptide. The form used in most of the strongest human trials.
- Kisspeptin-10 (KP-10): The shorter active fragment. The form most people buy, with thinner direct data and a minutes-long half-life.
- Pulsatile vs continuous: The axis is built to respond to pulses. Continuous, non-pulsatile exposure can desensitize the receptor and suppress hormones.
- OHSS: Ovarian hyperstimulation syndrome. The dangerous over-response to IVF triggers that kisspeptin appears to avoid.
- HSDD: Hypoactive sexual desire disorder. The low-desire condition studied in the kisspeptin sexual-brain trials.
How do you take Kisspeptin-10?
Dosing & Protocols
Dosing information is summarized from published research and community reports. This is not a prescribing guide. Consult a healthcare provider before starting any protocol.
View 3 routes and 4 protocols
Routes & Forms
| Route | Form | Clinical Range | Community Range |
|---|---|---|---|
| Intravenous infusion | Lyophilized powder reconstituted for clinical infusion | 1.5 to 4 mcg per kg per hour, up to 11 to 22.5 hours in trials | Rare outside research; infusion is impractical for self-use |
| Intravenous bolus | Lyophilized powder reconstituted for clinical bolus | 0.01 to 3.0 mcg per kg, maximal LH effect near 1 mcg per kg | Not a typical self-administration route |
| Subcutaneous injection | Lyophilized powder reconstituted with bacteriostatic water | Kisspeptin-54 used 1.6 to 12.8 nmol per kg as a single subcutaneous IVF trigger | 100 to 200 mcg per shot is community chatter, not a validated regimen |
Protocols
Acute LH stimulation (research) Clinical
- Dose
- About 1 mcg per kg
- Frequency
- Single intravenous bolus
- Duration
- Single administration
Produced a dose-dependent LH rise maximal at 1 mcg per kg in healthy men. Effect is minutes-scale and fades fast.
Sustained hormone support (research) Clinical
- Dose
- 1.5 to 4 mcg per kg per hour
- Frequency
- Continuous intravenous infusion
- Duration
- 11 to 22.5 hours
Raised testosterone in healthy and central-hypogonadal men. Impractical outside a research or clinical infusion setting because of the minutes-long half-life.
IVF oocyte-maturation trigger (research, kisspeptin-54) Clinical
- Dose
- 1.6 to 12.8 nmol per kg, second dose at 10 hours in some protocols
- Frequency
- Single or double subcutaneous dose
- Duration
- Single cycle trigger
This validated subcutaneous protocol used kisspeptin-54, not kisspeptin-10. Listed for honest context, not as a kisspeptin-10 regimen.
Grey-market self-dosing (cautionary) Anecdotal
- Dose
- 100 to 200 mcg per shot is community chatter
- Frequency
- Often daily or per-occasion subcutaneous
- Duration
- Variable
Not validated. Continuous, non-pulsatile exposure can downregulate the axis and suppress hormones, the opposite of the goal. Pulsatile, intermittent timing matters.
How this score is calculated →
What are the benefits of Kisspeptin-10?
Upside contribution: 2.04
| Dimension | Weight | Score | Visual | Weighted |
|---|---|---|---|---|
| Efficacy | 25% | 3.0 | 0.750 | |
| Breadth | 15% | 3.2 | 0.480 | |
| Evidence | 25% | 3.1 | 0.775 | |
| Speed | 10% | 3.5 | 0.350 | |
| Durability | 10% | 2.0 | 0.200 | |
| Bioindividuality | 15% | 3.2 | 0.480 | |
| Total | 3.035 |
Upside Rationale
The upside comes almost entirely from mechanism and from a first-rate academic research program, not from a thick kisspeptin-10-specific outcome file. Kisspeptin-10 is the upstream master switch of the reproductive axis, with reproducible LH and testosterone stimulation in men and dramatic egg-maturation efficacy in IVF, though that strongest signal used the longer kisspeptin-54. The boundary condition is real: the kisspeptin-10 form itself has small, infusion-based human data, so the dimension scores reward the quality and breadth of the evidence while staying honest that the form people buy is under-tested. What lifts kisspeptin-10 above the typical grey-market peptide is the source of its evidence. This is not a research-chemical reputation built on forum logs and animal studies. It is an independent academic program from one of the world's leading reproductive-endocrinology groups, published in journals like the New England Journal of Medicine, the Journal of Clinical Investigation, and JAMA Network Open, and grounded in genetics that prove the pathway controls human puberty. That pedigree is the reason the Evidence and Speed dimensions carry real weight, even as Durability and the practical kinetics pull the overall score back to Neutral.
Efficacy (3.0/5.0): Efficacy is solid for fertility and promising for libido, with the strongest data on the kisspeptin-54 form. In IVF, kisspeptin-54 triggered egg maturation across 53 women with embryo transfer in 92 percent, per Jayasena 2014, and reached 95 percent maturation in high-risk women, per Abbara 2015. The dedicated kisspeptin-10 work raised LH and testosterone in men but only on infusion, per George 2011. The sexual-desire trials show real brain and physiological signals rather than validated desire outcomes. For the validated fertility niche the efficacy is high, but for the uses people actually buy it for it is promising and soft, which lands this at the middle of the scale.
Breadth of Benefits (3.2/5.0): Breadth is moderate because kisspeptin-10 touches several applications, but all of them funnel through one axis. It works as an IVF trigger, per Abbara 2017, supports central hypogonadism in men, per George 2013, restores LH pulsatility in hypothalamic amenorrhea, and modulates sexual-brain processing in both sexes. That is genuine reach across male and female fertility, hormonal support, and sexual desire. The boundary is that every one of those benefits is downstream of the same HPG-axis activation, so this is narrower than a true multi-system intervention that hits independent pathways. The reproductive breadth is real and earns above-average credit, but it is not whole-body breadth.
Evidence Quality (3.1/5.0): Evidence quality is the differentiator and the reason this peptide rises above the grey-market baseline. It has independent academic randomized trials in top journals with real sample sizes of 53, 60, and 62, plus genetic-validation discovery papers like the puberty-failure mutation work, per Seminara 2003. The IVF and sexual-desire programs are Phase 2 quality, per Jayasena 2014. Two honest caps hold it back from a clear win. First, the strongest human trials used kisspeptin-54, not the kisspeptin-10 form on sale. Second, the kisspeptin-10-specific studies are tiny, with arms of four to six people, per George 2011. So the evidence is genuinely good for the molecule class but thin for the exact form, which keeps this just above the midpoint.
Speed of Onset (3.5/5.0): Speed is a clear strength and intrinsic to the molecule. Intravenous kisspeptin-10 produces an LH rise within about 30 minutes of dosing, per George 2011. The hormonal response is fast because kisspeptin acts directly at the top of the axis. The same speed cuts both ways: the effect arrives quickly and leaves quickly, since the peptide clears in minutes. For acute stimulation testing the rapid onset is genuinely useful, but the fast offset is what forces the impractical infusion dosing covered under Durability. The onset itself earns above-average credit here.
Durability (2.0/5.0): Durability is low because the effect is entirely administration-dependent and the half-life is minutes. Boluses give minutes-scale LH spikes, and sustained testosterone elevation in men required continuous infusion, per George 2011. There is no carry-over or disease-modifying durability claim in the human literature, so the axis returns to baseline when dosing stops. Worse, continuous non-pulsatile exposure can desensitize the receptor and suppress the axis, the opposite of the goal, shown in the hypothalamic amenorrhea infusion work, per Jayasena 2014. This is a maintain-with-precise-timing tool, not a reset, which keeps Durability near the bottom of the scale.
Bioindividuality Upside (3.2/5.0): Bioindividuality is moderate because response varies in predictable ways. The hypothalamic amenorrhea work showed an individualized dose window per patient, where infusion below a threshold restored pulsatility but above it suppressed the axis, per Jayasena 2014. The libido signal was strongest in people with lower baseline sexual quality of life, per Mills 2023. Kisspeptin works best where the axis is intact but under-driven, so a man with primary gonadal failure or a fully suppressed system will respond little. These predictable modifiers lift this above average, but they also mean a meaningful share of users see modest effects.
What are the risks & downsides of Kisspeptin-10?
Downside contribution: 1.49 (safety risks weighted extra)
| Dimension | Weight | Score | Visual | Weighted |
|---|---|---|---|---|
| Safety | 30% | 2.0 | 0.600 | |
| Side effects | 15% | 2.0 | 0.300 | |
| Cost | 5% | 3.0 | 0.150 | |
| Effort | 5% | 3.4 | 0.170 | |
| Opportunity | 5% | 2.8 | 0.140 | |
| Dependency | 15% | 2.3 | 0.345 | |
| Reversibility | 25% | 1.8 | 0.450 | |
| Total | 2.155 | |||
| Harm subtotal × 1.4 | 2.373 | |||
| Opportunity subtotal × 1.0 | 0.460 | |||
| Combined downside | 2.833 | |||
| Baseline offset (constant) | −1.340 | |||
| Effective downside penalty | 1.493 |
Downside Rationale
The downside is dominated by impractical kinetics and opportunity cost rather than acute danger. Kisspeptin-10 is intrinsically safe, a physiological hormone with no catastrophic signal and excellent trial tolerability, and it clears in minutes, so any unwanted effect resolves fast. The heavier weights come from the effort of dosing a peptide that needs infusion or frequent shots, the opportunity cost of an approved alternative existing for libido, and the genuine self-inflicted risk of axis suppression from continuous misuse. Dependency is low and reversibility is excellent because the molecule leaves the body quickly. The most exposed users are casual buyers who treat kisspeptin-10 like an on-demand peptide and assume a single subcutaneous shot will reproduce the trial effects. It will not, because the molecule is gone from the bloodstream within minutes, and the more someone overcorrects by dosing continuously, the more likely they are to desensitize the receptor and suppress the very hormones they meant to raise. None of these concerns are catastrophic, and none are intrinsic toxicity. They are practical, dosing-pattern, and access problems, which is exactly why the downside loads onto Effort, Opportunity, and Durability rather than Safety.
Safety Risk (2.0/5.0): Safety risk is low because kisspeptin-10 is a physiological hormone with excellent trial tolerability and no catastrophic signal. The sexual-desire trials reported it well tolerated with no adverse effects, per Mills 2023, and the IVF program saw no moderate, severe, or critical OHSS even in deliberately high-risk women, which is a safety advantage over the standard hCG trigger, per Abbara 2015. There is no anaphylaxis, organ failure, stroke, or death attributable to the peptide itself in the human literature, so no catastrophic floor applies. The residual points reflect unknown long-term repeated-dosing safety, investigational status, and the obvious caution zones of pregnancy and hormone-sensitive cancers where no data exist. This is a clean intrinsic safety profile.
Side Effect Profile (2.0/5.0): Side effects are minimal in the human record, which is unusual for an injectable peptide. Across the trials reviewed, kisspeptin was repeatedly described as well tolerated with no reported adverse effects, per Thurston 2022. There is no signature flushing, nausea, or blood-pressure reaction like the melanocortin peptides carry. The main practical concern is not a classic side effect but axis desensitization from continuous dosing, covered under Durability and Dependency, which is reversible. For a physiological hormone delivered at trial doses, the side-effect burden is genuinely light, which keeps this low.
Financial Cost (3.0/5.0): Cost is moderate and depends heavily on route. Grey-market research-chemical kisspeptin-10 powder is not expensive per vial, but the minutes-long half-life means matching trial effects needs frequent dosing or infusion, and clinical intravenous delivery is costly and impractical outside a research setting. The recurring spend on a form whose effective route is hard to reproduce at home is the relevant framing, not the sticker price of a single vial.
Time/Effort Burden (3.4/5.0): Effort is high and is one of the main reasons the score is capped. The trial effects required intravenous boluses or continuous infusion because kisspeptin-10 clears in minutes, per George 2011, so a single subcutaneous shot underperforms. Reproducing the evidence means frequent dosing or an infusion setup, plus reconstitution, injection, and precise pulsatile timing to avoid suppressing the axis. That is a far heavier logistics load than an on-demand peptide, which lifts this above average.
Opportunity Cost (2.8/5.0): Opportunity cost is real, especially for the libido use. For sexual desire, an approved, self-administered, on-demand option already exists in the melanocortin peptide PT-141, so money and effort spent chasing the unproven grey-market kisspeptin-10 route could go to a validated alternative. For fertility, the validated kisspeptin-54 trigger lives in clinic settings, not self-experimentation. The opportunity cost is meaningful but not extreme, since kisspeptin's upstream mechanism is genuinely distinct from anything approved, which keeps this in the middle of the range.
Dependency/Withdrawal (2.3/5.0): Dependency risk is low. Kisspeptin-10 produces no withdrawal syndrome or addictive craving, and the axis returns to baseline on cessation. The one real adaptation concern is receptor desensitization from continuous, non-pulsatile dosing, which suppresses rather than addicts and reverses once dosing stops or becomes appropriately pulsatile, per Jayasena 2014. That is functional and reversible, not dependence, which keeps this low.
Reversibility (1.8/5.0): Reversibility is excellent and is one of kisspeptin-10's genuine strengths. The peptide clears in minutes, so any unwanted effect resolves within hours and stopping returns the reproductive axis to baseline without a taper or lasting change. Even the desensitization from misuse is reversible once continuous exposure stops. There is no disease-modifying or permanent change in the human record, so a bad reaction does not linger, which lands this near the bottom of the scale, the good direction for a downside.
Is Kisspeptin-10 worth it?
Kisspeptin-10 sits at Neutral because it pairs a first-rate, mechanistically elegant research program with a thin direct data set for the exact form people buy and impractical kinetics. If you are a curious researcher, or you are in a supervised fertility setting, it is a genuinely interesting upstream switch for the reproductive axis with real Phase 2 efficacy as an OHSS-sparing IVF trigger and real early signals in sexual desire. If you are a casual buyer chasing libido or a post-cycle restart with a single subcutaneous shot, the picture is weaker: the strongest data used kisspeptin-54, the kisspeptin-10 studies used infusion, and the minutes-long half-life makes home dosing poorly aligned with the evidence. It remains investigational and grey-market, so most people seeking the libido use are better served by an approved option.
✅ Best for: Curious researchers who want to understand the master upstream switch of the reproductive axis and will judge it on the academic record rather than marketing. Supervised fertility settings where the OHSS-sparing trigger evidence applies, since that is where the strongest data live. Men with central, under-driven hypogonadism where upstream stimulation has direct proof-of-concept support. People with low sexual desire who understand the trial signals are early and used kisspeptin-54, and who will track their own response. Anyone who can source verified material and accept that this is investigational, not proven.
❌ Avoid if: You are pregnant, breastfeeding, or trying to conceive naturally outside a supervised clinic, since there are no safety data. You have any active or hormone-sensitive cancer, or a reproductive-cancer history, because reproductive-axis stimulation is an obvious caution zone with no data. You expect a single under-the-skin shot to reproduce the trial effects, because the minutes-long half-life means it will not. You plan continuous, more-is-better dosing, which can downregulate the axis and suppress your hormones. You cannot verify your source, since grey-market research-chemical purity and identity are unverified and contamination can exceed the intrinsic peptide risk.
What is Kisspeptin-10 best for?
The overall BioHarmony score reflects the intervention's primary evidence profile. These subratings are independent assessments per use case.
Hormonal / Endocrine: 5.0/10
Score: 5.0/10Hormonal and endocrine support is the core mechanism: kisspeptin-10 sits at the top of the reproductive axis and drives LH, FSH, and downstream sex hormones. Continuous infusion raised testosterone in healthy and central-hypogonadal men, per George 2013, and kisspeptin-54 increased LH pulsatility in women with hypothalamic amenorrhea, with peak LH pulse counts roughly three times vehicle, per Jayasena 2014. The catch is that the same paper showed continuous high-dose exposure desensitizes the axis, so the hormonal benefit depends on pulsatile, well-timed dosing. The mechanism is elegant and proven upstream, but practical, durable endocrine support from the kisspeptin-10 form remains unestablished, which keeps this at the threshold rather than higher.
Fertility (Male): 5.0/10
Score: 5.0/10Male fertility support has direct kisspeptin-10 evidence, which is why it clears the high bar even though the data set is small. Intravenous kisspeptin-10 produced a dose-dependent LH rise and, on continuous infusion, raised testosterone in healthy men, per George 2011, and restored LH and testosterone in men with central hypogonadism and type 2 diabetes, per George 2013. A head-to-head trial found kisspeptin-10 and kisspeptin-54 produced similar gonadotropin output in men, per Jayasena 2015. The mechanism is sound and the effect is reproducible, but the studies are tiny and used infusion, not the subcutaneous self-dosing people attempt, so the score stays just at the threshold.
Fertility (Female): 5.2/10
Score: 5.2/10Female fertility is the best-validated use, again driven by kisspeptin-54 rather than kisspeptin-10. A single subcutaneous dose triggered egg maturation at every dose tested across 53 women in IVF, with embryo transfer in 92 percent, per Jayasena 2014. In women at high risk of ovarian hyperstimulation syndrome, oocyte maturation reached 95 percent with no moderate, severe, or critical OHSS, per Abbara 2015, and a second dose at 10 hours raised the proportion achieving good oocyte yield without extra over-response, per Abbara 2017. This is genuine Phase 2 efficacy with a safety edge over the standard hCG trigger, so it earns the highest subrating despite the kisspeptin-10 versus kisspeptin-54 substitution.
| Use Case | Score | Summary |
|---|---|---|
| ⚖️ Libido / Sexual Health Primary | 4.8 | Libido is the strongest non-fertility signal and the main reason people seek kisspeptin-10, though the trial evidence used kisspeptin-54 rather than the kisspeptin-10 form on sale. In men with hypoactive sexual desire disorder, kisspeptin significantly modulated the sexual-processing brain network and increased penile tumescence to sexual stimuli by up to 56 percent versus placebo, per Mills 2023, with a parallel women's trial showing modulated sexual and attraction processing, per Thurston 2022. Earlier work enhanced limbic responses to sexual and bonding cues, per Comninos 2017. These are real, randomized, placebo-controlled signals, but they measure brain and physiological processing rather than a validated libido outcome, and the isoform gap caps the score below a clear win. |
Frequently Asked Questions
What is kisspeptin-10 and how does it work?
Kisspeptin-10 is the master upstream switch for the reproductive axis. It is the minimal active fragment of kisspeptin that activates the KISS1R receptor on GnRH neurons, which then drive pituitary LH and FSH and, in turn, your own testosterone or estradiol. People with loss-of-function receptor mutations fail to enter puberty, which proves how central this pathway is, per Seminara 2003. It sits one step above peptides like TRT by stimulating natural hormone production.
What is the difference between kisspeptin-10 and kisspeptin-54?
Kisspeptin-54 is the longer parent peptide, and kisspeptin-10 is its shorter active fragment, but most strong human trials used the kisspeptin-54 form even though people usually buy kisspeptin-10. A head-to-head study found the two produced similar gonadotropin output in men, per Jayasena 2015. The catch is half-life: kisspeptin-10 clears in minutes, so the dedicated kisspeptin-10 trials had to use infusion, per George 2011, which is the honest evidence gap.
What does the fertility and IVF evidence on kisspeptin show?
Kisspeptin works as an IVF egg-maturation trigger, with the strongest data using the kisspeptin-54 form. A single subcutaneous dose triggered maturation across 53 women with embryo transfer in 92 percent, per Jayasena 2014. In women at high OHSS risk, maturation hit 95 percent with no moderate or severe OHSS, per Abbara 2015. That safety edge over hCG is the real advance, though it remains investigational and clinic-only.
Does kisspeptin-10 boost libido and sexual desire?
Kisspeptin shows real but early sexual-desire signals, mostly using the kisspeptin-54 form in randomized trials. In men with low desire, it modulated the sexual-processing brain network and raised penile response to sexual stimuli by up to 56 percent versus placebo, per Mills 2023, with a parallel women's trial showing modulated arousal processing, per Thurston 2022. These measure brain and physiological processing, not a validated desire outcome. The melanocortin peptide PT-141 is the approved on-demand alternative.
How is kisspeptin-10 dosed and why is the half-life a problem?
Kisspeptin-10 dosing is hard because the peptide clears in minutes. Trials used intravenous boluses of 0.01 to 3.0 mcg per kg, maximal near 1 mcg per kg, or infusions of 1.5 to 4 mcg per kg per hour to sustain testosterone, per George 2011. The longer kisspeptin-54 parent clears around 28 minutes, per Dhillo 2005. A single under-the-skin shot of kisspeptin-10 cannot reproduce those effects, so frequent dosing or infusion is required.
Can kisspeptin-10 suppress your hormones instead of raising them?
Yes, continuous, non-pulsatile kisspeptin can downregulate the axis and suppress hormones, the opposite of the intended effect. The reproductive axis is built to respond to pulses, and constant high-dose exposure desensitizes the receptor, shown in the hypothalamic amenorrhea infusion work, per Jayasena 2014. Naive more-is-better dosing is the main self-inflicted risk, so timing and intermittency matter more than total dose.
Is kisspeptin-10 safe?
Kisspeptin-10 was well tolerated across human trials, with no catastrophic signal, because it is a physiological hormone rather than a foreign drug. The sexual-desire trials reported it well tolerated with no adverse effects, per Mills 2023, and the IVF program saw no severe OHSS in high-risk women, per Abbara 2015. The real caveats are unknown long-term repeated-dosing safety, investigational status, and grey-market sourcing with unverified purity.
Who is kisspeptin-10 actually for?
Kisspeptin-10 fits curious researchers and supervised fertility settings far more than casual buyers. Its validated wins are clinic-bound: the IVF trigger and central hypogonadism work used infusion or the kisspeptin-54 form, per Jayasena 2014. For the libido and post-cycle uses people buy it for, the data are thin and the route is wrong. It is investigational, grey-market, and not approved, so most people are better served by the approved option PT-141.
What could change Kisspeptin-10's score?
BioHarmony scores are living assessments. New research, regulatory changes, or personal context can shift the score up or down. These are the most likely scenarios that would change this intervention's rating.
The fastest path up is dedicated kisspeptin-10 outcome data using a practical route, and the fastest path down is a real safety signal on repeated dosing or confirmation that the kisspeptin-10 form underperforms kisspeptin-54 in practice. Because the current score rests on strong kisspeptin-54 evidence transferred to a thinly studied kisspeptin-10 form, even modest direct evidence in either direction would move it more than usual, with Efficacy and Evidence shifting first. The single biggest lever is the half-life. Most of the cap on this score traces back to the minutes-long kinetics that force infusion, so anything that solves the delivery problem, whether a longer-acting analogue or a validated frequent-dosing protocol that holds the pulsatile pattern, would lift Effort and Durability together and change the practical math. The pipeline is already moving in that direction, since pharma interest centers on longer-acting analogues precisely because native kisspeptin-10 kinetics are unsuitable for a chronic drug.
| Scenario | Dimension shifts | New Score |
|---|---|---|
| A practical kisspeptin-10 protocol shows real libido or fertility outcomes | Efficacy 3.0 to 4.0, Evidence 3.1 to 3.8, Effort 3.4 to 2.8 | 6.2 / 10 👍 Worth trying |
| A longer-acting kisspeptin-10 analogue removes the infusion burden | Effort 3.4 to 2.2, Durability 2.0 to 2.8 | 5.9 / 10 👍 Worth trying |
| Larger kisspeptin-10-specific trials confirm the kisspeptin-54 findings transfer | Evidence 3.1 to 3.7, Efficacy 3.0 to 3.5 | 6.0 / 10 👍 Worth trying |
| Repeated-dosing safety data stay clean but no outcome data emerge | Evidence 3.1 to 3.3 | 5.7 / 10 ⚖️ Neutral |
| A real safety signal emerges with repeated dosing | Safety 2.0 to 3.5, Side Effects 2.0 to 2.8 | 4.8 / 10 ⚖️ Neutral |
| Kisspeptin-10 is shown to clearly underperform kisspeptin-54 in practice | Efficacy 3.0 to 2.3, Evidence 3.1 to 2.6 | 5.3 / 10 ⚖️ Neutral |
Kisspeptin-54 achieved oocyte maturation in 95 percent of women at high risk of ovarian hyperstimulation syndrome, with no woman developing moderate, severe, or critical OHSS, a safety edge over the standard hCG trigger. Abbara 2015, J Clin Endocrinol Metab
In men with low sexual desire, kisspeptin increased penile tumescence to sexual stimuli by up to 56 percent versus placebo and significantly modulated the brain's sexual-processing network, the first evidence for a pharmacological option in men. Mills 2023, JAMA Network Open
Key Evidence Sources
- George 2011, J Clin Endocrinol Metab: intravenous kisspeptin-10 produced a dose-dependent LH rise maximal near 1 mcg per kg and raised testosterone on 22.5-hour infusion in healthy men.. Kisspeptin-10 dose-response RCT-grade trial; established KP-10 as the minimal fully active sequence in man.
- George 2013, Clin Endocrinol: kisspeptin-10 raised LH and testosterone in men with central hypogonadism and type 2 diabetes.. Kisspeptin-10 proof-of-concept study in central hypogonadism; infusion route.
- Jayasena 2015, Hum Reprod: kisspeptin-10 and kisspeptin-54 produced similar gonadotropin output in healthy men at matched doses.. Head-to-head kisspeptin-10 vs kisspeptin-54 trial; isoform comparison.
- Jayasena 2014, J Clin Invest: single subcutaneous kisspeptin-54 triggered egg maturation across 53 women in IVF with embryo transfer in 92 percent.. Landmark IVF trigger trial; used the related compound kisspeptin-54, not kisspeptin-10.
- Abbara 2015, J Clin Endocrinol Metab: kisspeptin-54 achieved 95 percent oocyte maturation in women at high OHSS risk with no moderate or severe OHSS.. Phase 2 OHSS-risk trial; used the related compound kisspeptin-54, not kisspeptin-10.
- Abbara 2017, Hum Reprod: a second kisspeptin-54 dose at 10 hours raised the proportion of women achieving good oocyte yield without extra over-response.. Phase 2 RCT; used the related compound kisspeptin-54, not kisspeptin-10.
- Jayasena 2014, J Clin Endocrinol Metab: continuous kisspeptin-54 increased LH pulsatility in women with hypothalamic amenorrhea, with desensitization at chronic high dose.. LH pulsatility trial; used the related compound kisspeptin-54; documents the continuous-dosing desensitization window.
- Comninos 2017, J Clin Invest: intravenous kisspeptin-54 enhanced limbic brain activity to sexual and bonding cues and attenuated negative mood in 29 healthy men.. Sexual-brain fMRI trial; used the related compound kisspeptin-54, not kisspeptin-10.
- Comninos 2018, JCI Insight: kisspeptin-54 modulated resting brain connectivity, predicting reduced sexual aversion in healthy men.. Resting-state connectivity trial; used the related compound kisspeptin-54, not kisspeptin-10.
- Thurston 2022, JAMA Network Open: a randomized crossover trial of kisspeptin-54 modulated sexual and attraction brain processing in premenopausal women with low sexual desire.. RCT in women with HSDD; used the related compound kisspeptin-54, not kisspeptin-10.
- Mills 2023, JAMA Network Open: kisspeptin-54 modulated the sexual-processing network and increased penile tumescence to sexual stimuli by up to 56 percent versus placebo in men with low desire.. RCT in men with HSDD; used the related compound kisspeptin-54, not kisspeptin-10.
- Dhillo 2005, J Clin Endocrinol Metab: first human male study measured the kisspeptin-54 plasma half-life at about 28 minutes.. Human pharmacokinetic anchor; parent compound kisspeptin-54 sets the half-life context.
- Seminara 2003, N Engl J Med: loss-of-function mutations in the kisspeptin receptor GPR54 cause failure of puberty, proving the pathway's central role.. Genetic-validation discovery paper; mechanistic context for kisspeptin signaling.
- Koysombat and Abbara 2025, Physiol Rev: a modern consolidated review of kisspeptin and neurokinin B reproductive-axis biology.. Recent review; mechanistic context for the kisspeptin reproductive axis.
What does the evidence say about Kisspeptin-10?
Evidence on this intervention is summarized across three complementary streams: contemporary clinical research, pre-RCT-era pharmacology and observational use, and the traditional medical systems that documented it first. Convergence across streams signals higher confidence; divergence is surfaced honestly.
Modern Clinical Research
Confidence: Medium
Citations: George 2011, Jayasena 2014, Abbara 2015, Mills 2023, Jayasena 2015
Traditional Medicine Systems
Confidence: Limited
Citations: Koysombat and Abbara 2025
Holistic Evidence for Kisspeptin-10
There is no traditional record to converge with, so the case rests entirely on the modern lens. Within that lens, mechanism and fertility data are consistent and strong, while the kisspeptin-10 form most people buy carries thinner direct evidence and impractical kinetics, which is the honest tension behind the Neutral score.
What to Track If You Try This
These are the data points that matter most while running a 30-day Experiment with this intervention.
How to read this section
- Pre
- Test or score before starting the protocol. Anchors a baseline.
- During
- Track while running the protocol so you can see if anything is changing.
- Post
- Re-test after a full cycle to confirm the change held.
- Up
- The marker should rise. For most positive outcomes, that is a good sign.
- Down
- The marker should fall. For most positive outcomes, that is a good sign.
- Stable
- The marker should hold steady. Big swings in either direction are a yellow flag.
- Watch
- Direction depends on dose, timing, and your baseline. Pay close attention to the trend.
- N/A
- No expected direction. The entry is there to anchor a baseline reading.
- Primary
- The Pulse dimension most likely to shift. Track this first.
- Secondary
- Also relevant, but a smaller or less consistent shift. Track if Primary is unclear.
Bloodwork to Order
Open These Markers In Your Dashboard
- LH During | Expected Up Pre | Expected Watch
- FSH During | Expected Up
- Testosterone During | Expected Up
- Estradiol During | Expected Watch
Pulse Dimensions to Watch
- Drive During | Expected Up | Primary
- Calm During | Expected Watch | Secondary
- Energy During | Expected Watch | Tertiary
Subjective Signals (Daily Voice Card)
- Sexual desire, arousal, and interest Scale 1-5 | During | Expected Up
- Mood and reduced sexual aversion or avoidance Scale 1-5 | During | Expected Watch
Red Flags: Stop and Consult
- Falling libido or hormone markers on continuous dosing, a sign of axis downregulation: stop and let the axis recover.
- Any active or hormone-sensitive cancer, or reproductive cancer history: do not use, no safety data.
- Pregnancy or attempting natural conception outside a supervised fertility setting: do not use.
- Unverified or research-chemical source with no purity or identity testing: do not inject.
Other interventions for libido
See all ratings →📊 How BioHarmony scoring works
BioHarmony translates a weighted expected-value calculation into a reader-facing 0–10 score. Tier bands: Skip 0–3.6, Caution 3.7–4.7, Neutral 4.8–5.7, Worth Trying 5.8–6.9, Strong Recommend 7.0–7.9, Top-tier 8.0+.
Harm-type downsides (safety risk, side effects, reversibility, dependency) carry a 1.4× precautionary multiplier. Harm weighs more than benefit. Opportunity-type downsides (financial cost, time/effort, opportunity cost) are subtracted at face value.
Use case subratings are independent assessments of how well the intervention addresses specific health goals. They are not components of the overall score. Each subrating reflects the scorer's judgment based on use-case-specific evidence, safety, and effect sizes.
Every dimension is evaluated on a 1–5 scale, and the baseline (1) is subtracted before weighting. A perfect intervention with zero downsides contributes zero penalty rather than a residual floor, so top-tier scores are actually reachable.
EV = Upside − Downside
EV = 2.035 − 1.493 = 0.542
Formula v0.5 maps EV = 0 to score 5.0. Above neutral, 1 EV point equals 1 score point. Below neutral, 1 EV point equals about 0.71 score points, so EV = −7 reaches 0.0 while EV = +5 reaches 10.0. Both sides use the full 5-point half-scale.
Score = 5 + (0.542 / 5) × 5 = 5.5 / 10
